Clinically Actionable Tumor-Associated Antigens in Prostate Cancer
Expression Profiles And Prognostic Implications Of Clinically Actionable Tumor-Associated Antigens Across Diverse Clinicopathological Subtypes of Prostate Cancer: a Bidirectional Cohort Study
The goal of this observational study is to evaluate and validate the expression and prognostic value of 15 ADC-targetable membrane proteins (PSMA, B7-H3, STEAP1, TROP2, KLK2, HER2, TF, HER3, DLL3, SEZ6, STEAP2, MUC1, NECTIN4, FAP, PDL1) in patients with diverse clinicopathological subtypes of prostate cancer (e.g. primary and different metastatic types，HSPC and CRPC， PC with neuroendocrine differentiation, cribriform/intraductal carcinoma).
The main questions it aims to answer are:
- What is the expression profile of 15 clinically actionable targes in tumor tissues from patients with diverse clinicopathological subtypes of prostate cancer?
- Can the prognostic value of these targets (e.g. association with overall survival) identified in a retrospective cohort be validated in an independent prospective cohort? Researchers will head-to-head compare the expression levels among different targets and across different disease stages/metastatic site. Researchers will also assess whether the targets showing prognostic significance in the retrospective cohort can also predict survival outcomes in the prospective cohort.
Participants in the retrospective cohort have already provided archived tissue samples and clinical data. Participants in the prospective cohort (metastatic prostate cancer patients) will be invited to provide residual tumor tissue samples obtained during standard care and will be followed up regularly for clinical outcomes.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
- Study Type This is a single-center, observational cohort study incorporating both retrospective and prospective components. It is a non-interventional study that does not involve assignment of participants to specific interventions.
- Objectives
Primary Objectives:
- To determine the protein expression profile (positive rate, expression level) of 15 membrane targets (PSMA, B7-H3, STEAP1, TROP2, KLK2, HER2, TF, HER3, DLL3, SEZ6, STEAP2, MUC1, NECTIN4, FAP, PDL1) in diverse clinicopathological subtypes of prostate cancer (HSPC and CRPC，primary and metastatic lesions include lymph node, bone and visceral metastasis, etc.).
- To characterize the molecular subtypes of prostate cancer based on the expression profiles of AR, PSA, PSMA, Syn, CgA, CD56, p53, RB1, and PTEN across different disease states and metastatic sites.
- To validate the association between the expression of prognostically significant targets (identified in the retrospective cohort) and overall survival (OS) in an independent, prospectively enrolled cohort of prostate cancer patients.
Secondary Objectives:
- To compare the expression of each target between matched CSPC and mCRPC samples from the same patients.
- To compare the expression of each target across different metastatic sites (e.g., bone, lymph node, viscera) in mCRPC.
- To analyze the association between target expression and clinical outcomes [biochemical recurrence-free survival (BFS), metastasis-free survival (MFS)] in patients with CSPC.
- To explore co-expression patterns of the targets and their correlation with clinicopathological features.
3.Study Design
Retrospective Cohort:
Population: Patients treated at Peking University First Hospital between 2000-2022.
Cohort 1: Primary Tumor Cohort - This cohort includes patients with CSPC or CRPC, or those with special pathological structures, for whom primary tumor tissue (from biopsy or surgery) is available.
Cohort 2: Lymph Node Metastasis Cohort - This cohort includes patients with CSPC or CRPC for whom lymph node metastasis tissue is available (from biopsy or surgery) .
Cohort 3: Bone Metastasis Cohort - This cohort includes patients with CSPC or CRPC, for whom bone metastasis tissue is available (from biopsy or surgery).
Cohort 4: Visceral Metastasis Cohort - This cohort includes patients with CSPC or CRPC, for whom visceral (e.g., liver, lung) metastasis tissue is available.
Procedures: Archived FFPE tissue blocks will be retrieved for immunohistochemistry (IHC) staining. Clinical and follow-up data will be extracted from medical records.
Prospective Cohort:
Population: Newly diagnosed metastatic prostate cancer patients at Peking University First Hospital from January 1, 2026.
Cohort 5: Prospective Validation Cohort - This cohort will consist of patients with metastatic prostate cancer (mHSPC or mCRPC), from whom tissue samples will be collected prospectively along with their clinical data.
Procedures: Eligible patients will provide informed consent. Residual tumor tissue obtained during standard-of-care biopsies or surgeries will be collected for IHC staining. Patients will be followed prospectively at defined intervals to collect treatment and outcome data.
4.Methods Laboratory Assessment (for both cohorts): IHC will be performed on FFPE tissue sections using validated antibodies against the eight targets (as specified in the protocol: e.g., HER2: ab2142275; TROP2: ab214488; etc.). Staining will be evaluated by pathologists blinded to clinical outcomes. IHC score 0-3,0=negative/none,1=weak,2=moderate,3=strong. A modified H-score ([1×% weak staining + 2×% moderate staining + 3×% strong staining], range 0-300) will be used for quantification.
Data Collection: Clinical data (demographics, laboratory assessment (tPSA、LDH levels)，imaging data(ultrasound, MRI, CT, PET, providing TNM staging results, treatment history, pathology reports) and outcome data (biochemical recurrence, metastasis, death) will be collected retrospectively from databases/records for the retrospective cohort and prospectively during follow-up visits for the prospective cohort.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienorte
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Peking University First Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Probenahmeverfahren
Studienpopulation
- Retrospective Cohorts: These four groups are defined by the origin of the archived tumor tissue specimen at Peking University First Hospital (2000-2025). Each cohort includes patients across the spectrum of disease states (castration-sensitive [CSPC] and castration-resistant [CRPC] prostate cancer) and those with special clinicopathological subtypes (e.g., neuroendocrine differentiation, cribriform/intraductal carcinoma).
- Prospective Validation Cohort: This group will consist of patients with metastatic prostate cancer recruited at Peking University First Hospital starting January 1, 2026. Participants will provide informed consent for the use of residual tumor tissue (from any anatomic site) obtained during standard clinical care and for prospective clinical follow-up.
The core material for analysis is formalin-fixed, paraffin-embedded (FFPE) tumor tissue from all participants, which will be subjected to immunohistochemical (IHC) staining for biomarker evaluation.
Beschreibung
Inclusion Criteria:
For the Retrospective Cohorts (mCRPC, CSPC, Special Pathology):
- Patients with a pathological diagnosis of prostate cancer.
- Treated at Peking University First Hospital between January 2000 and 2025.
- Availability of adequate, qualified formalin-fixed, paraffin-embedded (FFPE) tumor tissue blocks for research.
- Availability of essential clinical and follow-up data in medical records.
For the Prospective Cohort:
- Age ≥ 18 years.
- CSPC, primarily includes patients who underwent neoadjuvant therapy and have paired pre- and post-treatment biopsy and surgical specimens; or patients with special clinicopathological subtypes.
- metastatic prostate cancer patients.
- Planned or recent (within 6 months prior to enrollment) acquisition of tumor tissue (from metastasis or primary site) as part of standard clinical care, with sufficient residual tissue available for the study.
- Willing and able to provide written informed consent.
Exclusion Criteria:
For All Cohorts:
- Tumor tissue sample is of insufficient quality or quantity for immunohistochemical (IHC) analysis.
- Essential clinical or outcome data are missing or irretrievable, which would preclude meaningful analysis.
Specifically for the Prospective Cohort:
- Any condition that, in the investigator's judgment, would significantly compromise the patient's ability to provide informed consent or comply with the study follow-up procedures.
- Patient refusal to participate.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Primary Tumor Cohort
This retrospective cohort consists of patients with prostate cancer (encompassing castration-sensitive [CSPC], castration-resistant [CRPC] disease states, and those with special clinicopathological subtypes) for whom primary tumor tissue (from biopsy or radical prostatectomy) is available.
Archived FFPE specimens were obtained at Peking University First Hospital between 2000 and 2025.
This is an observational cohort.
No study intervention is administered.
|
Immunohistochemistry staining will be performed on formalin-fixed, paraffin-embedded (FFPE) prostate cancer tissue sections to quantitatively assess the expression levels of eight membrane protein targets: PSMA, HER2, TROP2, NECTIN4, DLL3, STEAP1, B7-H3, and PDL1.
This is a laboratory-based biomarker analysis and does not constitute a therapeutic intervention for participants.
|
|
Lymph Node Metastasis Cohort
This retrospective cohort consists of patients with prostate cancer (encompassing CSPC, CRPC disease states, and those with special clinicopathological subtypes) for whom lymph node metastasis tissue is available.
Archived FFPE specimens were obtained at Peking University First Hospital between 2000 and 2025.
This is an observational cohort.
No study intervention is administered.
|
Immunohistochemistry staining will be performed on formalin-fixed, paraffin-embedded (FFPE) prostate cancer tissue sections to quantitatively assess the expression levels of eight membrane protein targets: PSMA, HER2, TROP2, NECTIN4, DLL3, STEAP1, B7-H3, and PDL1.
This is a laboratory-based biomarker analysis and does not constitute a therapeutic intervention for participants.
|
|
Bone Metastasis Cohort
This retrospective cohort consists of patients with prostate cancer (encompassing CSPC, CRPC disease states, and those with special clinicopathological subtypes) for whom bone metastasis tissue is available.
Archived FFPE specimens were obtained at Peking University First Hospital between 2000 and 2025.
This is an observational cohort.
No study intervention is administered.
|
Immunohistochemistry staining will be performed on formalin-fixed, paraffin-embedded (FFPE) prostate cancer tissue sections to quantitatively assess the expression levels of eight membrane protein targets: PSMA, HER2, TROP2, NECTIN4, DLL3, STEAP1, B7-H3, and PDL1.
This is a laboratory-based biomarker analysis and does not constitute a therapeutic intervention for participants.
|
|
Visceral Metastasis Cohort
This retrospective cohort consists of patients with prostate cancer (encompassing CSPC, CRPC disease states, and those with special clinicopathological subtypes) for whom visceral metastasis (e.g., liver, lung) tissue is available.
Archived FFPE specimens were obtained at Peking University First Hospital between 2000 and 2025.
This is an observational cohort.
No study intervention is administered.
|
Immunohistochemistry staining will be performed on formalin-fixed, paraffin-embedded (FFPE) prostate cancer tissue sections to quantitatively assess the expression levels of eight membrane protein targets: PSMA, HER2, TROP2, NECTIN4, DLL3, STEAP1, B7-H3, and PDL1.
This is a laboratory-based biomarker analysis and does not constitute a therapeutic intervention for participants.
|
|
Prospective Validation Cohort
This is a prospective, observational cohort.
It will enroll metastatic prostate cancer patients (mHSPC or mCRPC) at Peking University First Hospital starting January 1, 2026.
Participants will provide informed consent.
Residual tumor tissue (from any site) obtained during standard-of-care procedures will be collected for biomarker analysis, and participants will be followed prospectively for clinical outcomes.
No study intervention is administered.
|
Immunohistochemistry staining will be performed on formalin-fixed, paraffin-embedded (FFPE) prostate cancer tissue sections to quantitatively assess the expression levels of eight membrane protein targets: PSMA, HER2, TROP2, NECTIN4, DLL3, STEAP1, B7-H3, and PDL1.
This is a laboratory-based biomarker analysis and does not constitute a therapeutic intervention for participants.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Expression Profile in the Retrospective Prostate Cancer Cohort
Zeitfenster: Baseline (at time of metastatic site sample acquisition)
|
The protein expression profiles of 15 tumor-associated antigens (PSMA, B7-H3, STEAP1, TROP2, KLK2, HER2, TF, HER3, DLL3, SEZ6, STEAP2, MUC1, NECTIN4, FAP, PDL1) and molecular subtype markers (AR, PSA, Syn, CgA, CD56, p53, RB1, and PTEN) in tumor tissues from the four retrospective site-based cohorts (Primary Tumor, Lymph Node Metastasis, Bone Metastasis, Visceral Metastasis).
Measure: Expression level assessed by IHC score (0-3) , modified H-score (0-300) (positive expression defined as a H-score > 20) for each target within each cohort.
|
Baseline (at time of metastatic site sample acquisition)
|
|
Validation in the Prospective Cohort
Zeitfenster: From date of prospective cohort enrollment until death from any cause, assessed up to 3 years
|
The association between the expression status (positive/negative or H-score level) of prognostically significant ADC targets (identified in the retrospective cohort) and Overall Survival (OS) in the prospectively enrolled mCRPC validation cohort. This is a confirmatory analysis. Measure: Hazard Ratio (HR) with 95% Confidence Interval (CI) from Cox proportional hazards model. |
From date of prospective cohort enrollment until death from any cause, assessed up to 3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Target Expression Difference: Primary Tumor vs. Paired Metastasis
Zeitfenster: Baseline (at time of matched sample acquisition)
|
The difference in expression level (IHC score or H-score) for each target between primary tumor and matched metastasis (from any site) from the same patients, where such paired samples are available in the retrospective cohorts. Measure: IHC score or H-score. |
Baseline (at time of matched sample acquisition)
|
|
Target Expression Difference: Across Different Metastatic Sites
Zeitfenster: Baseline
|
The difference in expression level (IHC score or H-score) for each target among the different metastatic sites (Lymph Node, Bone, Viscera) in the retrospective cohorts. Measure: IHC score or H-score. |
Baseline
|
|
Target Expression in Special Clinicopathological Subtypes (Subgroup Analysis)
Zeitfenster: Baseline
|
The expression profile of the 15 tumor-associated antigens in tumor tissues with neuroendocrine differentiation or cribriform/intraductal carcinoma (CF/IDC), analyzed as a subgroup across retrospective cohorts. Measure: IHC score or H-score. |
Baseline
|
|
Prognostic Association in Retrospective Prostate Cancer Cohort
Zeitfenster: From date of radical prostatectomy until biochemical recurrence, metastasis, or death, assessed up to 10 years
|
The association between tumor-associated antigens expression status and clinical outcomes in the retrospective retrospective prostate cancer cohort, with sub-analysis by disease state (CSPC vs. CRPC). Measure: Hazard Ratios (HR) for Metastasis-free Survival (MFS) and (for CSPC sub-group) Biochemical Recurrence-free Survival (BFS). |
From date of radical prostatectomy until biochemical recurrence, metastasis, or death, assessed up to 10 years
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Co-expression and Complementary Expression Patterns of ADC Targets
Zeitfenster: Baseline
|
Exploration of co-expression patterns among the 15 tumor-associated antigens and their correlation with clinicopathological features.
Characterization of molecular subtypes based on expression profiles of key markers (e.g., AR, Syn, etc.) across different anatomic sites and disease states
|
Baseline
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Genitale Neubildungen, männlich
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Genitalerkrankungen, männlich
- Prostataerkrankungen
- Männliche Urogenitalerkrankungen
- Prostataneoplasmen
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Zytologische Techniken
- Histozytochemie
- Histologische Techniken
- Immunologische Techniken
- Histozytologische Präparationstechniken
- Immunhistochemie
- Staining and Labeling
Andere Studien-ID-Nummern
- 2022CR16
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .